All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. What are the recommended clinical assessment and screening tests during pregnancy?

    KCE Reports 248 (2015)

    https://kce.fgov.be/en/what-are-the-recommended-clinical-assessment-and-screening-tests-during-pregnancy

  2. Use of pneumococcal vaccines in the elderly: an economic evaluation

    KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.

    https://kce.fgov.be/en/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation

  3. Seasonal influenza vaccination: priority target groups – Part I

    KCE Reports 162 (2011)

    https://kce.fgov.be/en/seasonal-influenza-vaccination-priority-target-groups-%E2%80%93-part-i

  4. Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

    KCE Reports 204 (2013)

    https://kce.fgov.be/en/seasonal-influenza-vaccination-prioritizing-children-or-other-target-groups-part-ii

  5. Prevention of preterm birth in women at risk: selected topics

    KCE Reports 228 (2014)

    https://kce.fgov.be/en/prevention-of-preterm-birth-in-women-at-risk-selected-topics

  6. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

    KCE Reports 243 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-diagnosis-and-follow-up-in-birt-hogg-dub%C3%A9-syndrome-familial-atypical-multiple

  7. Oncogenetic testing for persons with hereditary endocrine cancer syndromes

    KCE Reports 242 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-for-persons-with-hereditary-endocrine-cancer-syndromes

  8. Oncogenetic testing for Lynch syndrome and familial adenomatous polyposis

    KCE Reports 220 (2014)

    https://kce.fgov.be/en/oncogenetic-testing-for-lynch-syndrome-and-familial-adenomatous-polyposis

  9. Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li Fraumeni syndrome and Cowden syndrome

    KCE Reports 236 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-and-follow-up-for-women-with-familial-breastovarian-cancer-li-fraumeni-syndrome

  10. Non-invasive markers of subclinical atherosclerosis for predicting a primary cardiovascular event: a rapid systematic review

    KCE Reports 244 (2015)

    https://kce.fgov.be/en/non-invasive-markers-of-subclinical-atherosclerosis-for-predicting-a-primary-cardiovascular-event-a

  11. Informed choice on breast cancer screening: messages to support informed decision

    KCE Reports 216 (2014)

    https://kce.fgov.be/en/informed-choice-on-breast-cancer-screening-messages-to-support-informed-decision

  12. HPV Vaccination for the Prevention of Cervical Cancer in Belgium: Health Technology Assessment

    KCE Reports 64 (2007)

    https://kce.fgov.be/en/hpv-vaccination-for-the-prevention-of-cervical-cancer-in-belgium-health-technology-assessment

  13. Effects and costs of pneumococcal conjugate vaccination of Belgian children

    KCE Reports 33 (2006)

    https://kce.fgov.be/en/effects-and-costs-of-pneumococcal-conjugate-vaccination-of-belgian-children

  14. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood

    KCE Reports 155 (2011)

    https://kce.fgov.be/en/cost-effectiveness-of-10-and-13-valent-pneumococcal-conjugate-vaccines-in-childhood

  15. Cost-effectiveness analysis of rotavirus vaccination of Belgian infants

    KCE Reports 54 (2007)

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-rotavirus-vaccination-of-belgian-infants
  16. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium

  17. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening

    KCE Reports 238 (2015)

    https://kce.fgov.be/en/cervical-cancer-screening-program-and-human-papillomavirus-hpv-testing-part-ii-update-on-hpv-primary

  18. Cervical Cancer Screening and Human Papillomavirus (HPV) Testing

    KCE Reports 38 (2006) 2nd print (1st print, September 2006)

    https://kce.fgov.be/en/cervical-cancer-screening-and-human-papillomavirus-hpv-testing
  19. CP241

    Cardiovascular pre-participation screening in young athletes

    KCE Reports 241 (2015) About 1 million young Belgians (14-34) are member of a sportsclub, and in addition, many others are practicing a sport outside the structure of a sport organization. As we all know, sport is very good for your health. But, unfortunately, but luckily very seldom, it can lead to a sudden death due to cardiac failure. The authorities already have made a lot of effort to limit the risk for sporters. But can we avoid this kind of shocking events by submitting young sporters, without heart complaints, to a systematic heart examination?

    https://kce.fgov.be/en/cardiovascular-pre-participation-screening-in-young-athletes

  20. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effectiveness-study

Pages